Biotricity Inc. (“Biotricityy”) announced its Health Canada approval for expansion into the US$1.56 billion Canadian Cardiology Devices market. Cardiovascular disease imposes a staggering US$21.2 billion annual cost in Canada alone, accounting for 11.6% of the entire Canadian health care cost. Health Canada’s approval of Biotres, Biotricity’s flagship product, is a critical step in the Company’s quest to address the needs of more than 2.4 million Canadians living with heart disease and related conditions. This milestone achievement underscores Biotricity’s dedication to reshaping healthcare through innovation.

Biotricity strengthens its foundation for growth, achieves lower cost of sales, expanding margins of 73% and increased device sales, for third quarter of Fiscal Year 2024

February 21, 2024

Biotricity Inc. (“Biotricity) today announced its financial results for the third quarter of fiscal 2024 year and (unaudited) ended December 31, 2023. Dr. Waqaas Al-Siddiq, Biotricity Founder & CEO, said, “This quarter was marked by record margins, lowered costs and increasing revenues, supporting our path towards positive cashflow. The major theme for us was on long-term building- which meant reshaping our sales force to focus on efficiencies, longer sales cycles, larger accounts and independent hospitals and Group Purchasing Organizations- the necessary steps towards establishing recurring technology subscriptions and long-term growth.

February 2024

Biotricity receives Health Canada clearance for Biotres

Biotricity strengthens its foundation for growth, achieves lower cost of sales, expanding margins of 73% and increased device sales, for third quarter of Fiscal Year 2024